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Analysis of Presentation, Management and outcome following 
Neoadjuvant therapy in Carcinoma Rectum  
 
BACKGROUND: 
The potential for curative resection is the most important component of 
multimodality treatment of Rectal cancer. In locally advanced Rectal 
cancer lymph node involvement and positive circumferential resection 
margin are common which leads to local recurrence and metastatic 
disease. Postoperative chemo Radiotherapy significantly improves local 
recurrence control and improved overall survival. Several studies have 
shown that Preoperative Chemo Radiotherapy has increased local control 
rates, tumor down staging, sphincter saving procedures and enhancing 
resectability 
AIM: 
The aim of the study is to analyze the surgical outcome following 
neoadjuvant Chemo Radiotherapy in patients with locally advanced 
operable Rectal cancer (T3, T4 and Node positive tumor). To analyze 
whether preoperative Chemo Radiotherapy is beneficial to the patient or 
not, Analyzing the primary end points and analyzing Secondary 
endpoints. 
MATERIALS & METHODS 
This retrospective study was conducted in the Department of Surgical 
Gastroenterology, Rajiv Gandhi Government General Hospital, Madras 
Medical college, Chennai. From March  2012 to February  2014. The study was 
approved by the medical ethics committee of the hospital. 
15 patients with advanced carcinoma rectum were included in the study. 
Eligibility Criteria 
• All patients with locally advanced operable rectal cancer i.e. T3, T 4, 
node positive tumors without distant metastasis,Patients with 
histologically confirmed adenocarcinoma within 12 cm from anal 
verge(locally advanced Rectal carcinoma in Middle and Lower third of 
Rectum),Patients with Carcinoma Lower third Rectum with upper Anal 
canal involvement, Radiological evidence of mesorectal invasion  
• Exclusion Criteria- Patients who previously had cancer other than basal 
cell carcinoma of skin, Patients who had received chemotherapy or 
radiotherapy,  Patients with contraindications to chemoradiotherapy,  
Distant metastasis, Patients with poor performance status  
 
Preoperative evaluation- Loco regional staging was done with contrast 
enhanced CT of abdomen and pelvis, Endorectal ultrasound and cystoscopy in 
cases suspected of bladder invasion.. Distant metastasis was excluded by 
contrast enhanced CT of abdomen and pelvis, chest X-ray and if necessary a 
CT chest. Colonoscopy was done to rule out synchronous lesions. A basic work 
up including complete hemogram, Renal function tests, Liver function tests,  
Tumor markers –CEA, Pulmonary function tests and Cardiac tests – ECG 
&Echocardiogram was done to rule out any major illness and to confirm the 
patient’s fitness for surgery. Treatment Preoperative external beam 
radiotherapy was given for a total dose of 50.4 Gy in 28 fractions of 180 cGy 
each, five times per week for total duration of five and a half weeks.. The 
radiotherapy was given to include the tumor area and its drainage lymph nodes. 
RESULTS  
 
 
Neoadjuvant chemo radiotherapy helps significant downsizing and 
downstaging of tumor as it causes tumor shrinkage. In this study downsizing 
occurred. This is almost in accordance with other studies which have shown 
similar significant regression of the tumor after chemoradiotherapy. 
Among fifteen patients Fourteen patients underwent surgery at six weeks 
after chemoradiotherapy; one patient had surgery after seven weeks in post 
chemoradiotherapy period. Five patients underwent anterior resection. Ten 
patients underwent abdominoperineal resection. Of the twelve patients who had 
been treated for   locally advanced carcinoma Rectum for whom APER was 
planned, a sphincter conservation surgery was possible in two of them after 
neoadjuvant chemoradiotherapy and those patients underwent anterior resection. 
Before neoadjuvant chemoradiotherapy only three anterior resections were 
planned. After it, five anterior resections were done with covering ileostomy 
done to protect the anastomosis as well as to reduce leak related complications 
CONCLUSION  
Neoadjuvant chemoradiotherapy given in operable locally advanced mid 
and low rectal cancers causes significant downsizing, downstaging of the 
tumour, increases the rate of sphincter conservation surgeries. The toxicity of 
chemoradiotherapy is minimal, patient compliance is good. The postoperative 
complications are not increased and it helps decrease the incidence of local 
recurrence .The effect on survival has to be determined on long term follow up 
only. Hence it is beneficial to administer it to patients with locally advanced 
operable mid and low rectal cancers. 
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INTRODUCTION 
Multimodality treatment is the most important component of 
potential for curative resection of Rectal cancer.  Local recurrence and 
metastatic disease in locally advanced Rectal cancer are due to positive 
circumferential resection margin and lymph node involvement. Overall 
survival and local recurrence control are improved by Postoperative chemo 
Radiotherapy. Preoperative Chemo Radiotherapy has increased local 
control rates, tumor down staging, sphincter saving procedures and 
enhancing resectability a fact shown by several studies. This study on 
Neoadjuvant Chemoradiotherapy for carcinoma Rectum evaluates 
presentation, potential benefits and outcome following multimodality 
treatment for locally advanced operable Rectal cancer.  
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RATIONALE FOR THE STUDY 
Trials comparing different treatment modalities for carcinoma 
Rectum have arrived at different conclusions. This study is to analyze of 
Presentation, Management and outcome following Neoadjuvant therapy in 
Carcinoma Rectum” in our super specialty department, hence to formulate 
a standard method in locally advanced Rectal cancer  for patient selection, 
type of anastomosis and perioperative care to achieve good outcome after 
neoadjuvant therapy. 
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AIM OF THE STUDY 
The aim of the study is to analyze the surgical outcome following 
neoadjuvant Chemo Radiotherapy in patients with locally advanced 
operable rectal cancer (T3, T4 and Node positive tumor).  
The main aim is to analyze whether preoperative Chemo 
Radiotherapy is 
1) Beneficial to the patient or not. 
2) Analyzing the primary end points- are downsizing of tumor, 
down staging of the tumor, sphincter preserving rates, Toxicity of Chemo 
Radiotherapy regimen  and compliance for the regimen 
3)  Analyzing Secondary endpoints- which are analyzed in other 
trials are the incidence of local recurrence, distant metastases. The 
incidence of peroperative complications and postoperative complications 
also analyzed. 
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REVIEW OF LITERATURE 
Colorectal cancer accounts for about a third of all colorectal 
malignancies and second commonest cause of cancer death. Many of the 
locally advanced cancer Rectum are unresectable at time of presentation. 
Lack of appreciable improvements in the past decades made many 
clinicians and investigators to look for other better and effective different 
therapeutic modalities in addition to surgery In 1970s several clinicians 
reported favorable and conflicting results on this. Results revealed that 
chemotherapy in addition to Radiotherapy had place in the management of 
potentially operable rectal cancer. 
     In 1969 Moertel and Reitemeier showed that 
ChemoRadiotherapy (external beam RT and 5FU) resulted in a 
significantly better subjective as well as objective results in the treatment 
of stage ii/ iii gastrointestinal malignancies. 
    Incidence of sporadic colorectal cancer increases significantly 
above 45 or 50 years of all age groups, making age a factor in colorectal 
carcinoma. Lack of physical activity with obesity and Ingestion of high fat 
and high red-meat, leads to increased incidence and mortality rates 
observed in etiology of Rectal cancer.  
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ANATOMY OF RECTUM 
• Rectum is 12 to 15 cm in length, located in pelvis  
• Lacks taeniaecoli or epiploic appendices 
• occupies the curve of the sacrum in the true pelvis  
• Anterior surface is partly intraperitoneal  and posterior surface 
and mesorectum are almost completely extra peritoneal 
• Rectum has three curves, -valves of Houston. The middle 
valve folds to the left 
• The endopelvic fascia lines the walls and floor of the pelvis.  
• Fascia propria is a thin condensation of the endopelvic fascia 
that forms an envelope around the mesorectum  Waldeyer’s 
fascia posterior fascia, connecting the presacral fascia to the 
fascia propria at the level of S4 
• Sympathetic supply of Rectum  from the preganglionic 
lumbar splanchnic L1 to L3, synapse in the   Preaortic plexus, 
postganglionic elements follow the branches of the IMA  
• Pelvic plexus is adherent to the pelvic sidewalls and is 
adjacent to the lateral stalks 
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• Parasymphathetics from S 2,3,4 
•  Dissection between the fascia propria and presacral fascia 
follows the principles of surgical oncology   
• Blood supply from Inferior mesenteric artery, Internal iliac 
artery 
• Venous drainage into inferior mesenteric vein and to iliac 
veins 
• Lymphatics and lymph nodes and vessels located in 
retroperitoneum.  
MODE OF SPREAD OF RECTAL CANCER 
Carcinoma Rectum spreads through various routes –  
• Direct 
• Lymphatic, 
• Venous 
• Transcoelomic   
• Implantation 
Direct spread of tumor can result in proximal, distal, in longitudinal 
and transverse directions.    In 1983 Williams et al revealed that distal 
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intramural spread greater than 1 cm is uncommon. There is no evidence to 
show a distal margin of 5cms in the resected specimen improves survival 
by decreasing recurrence. 
   Radial spread from posterior wall of Rectum involve Waldayer’s 
fascia through mesorectal involvement. Tumors in Anterior wall of 
Rectum in males below the level of peritoneal reflection may involve 
Prostate, Seminal vesicle or Urinary bladder. William et al endorsed that 
leaving residual tumor tissue in the pelvis is the cause for local recurrence. 
LYMPHATIC SPREAD 
Rectal malignancies can spread in upward, downward and radial 
directions. Discontinuous spread occurs in 30% cases. Extensive lateral 
spread occurs in extra peritoneal tumors and it is uncommon in tumors 
above peritoneal reflection. 
 Nodes involved in rectal malignancy are Mesorectal nodes, Iliac 
nodes and anal canal involvement results in enlargement of inguinal nodes. 
Blood spread can occur to Liver, Lung, Kidneys, Bones and ovaries. 
Prognosis is worse in venous invasion.  
 8 
 
Extramural and intra mural veins of the Rectum can be involved in 
advanced malignancies and worse prognosis is in extramural vein 
involvement. 
LOCAL RECURRENCE IN RECTAL CANCER 
ROLE OF TOTAL MESORECTAL EXCISION  
Total MesoRectal excision is precise sharp dissection around the 
integral mesentery of Rectum. Lymph nodes, loose areolar tissue and 
blood vessels in mesorectum harboring subclinical micro metastatic tissue 
are removed enbloc with tumor bearing Rectum with adequate oncological 
clearance. 
Total MesoRectal Excision was introduced by Heald in 1982.2 
 Arbman3 et al in 1996 compared their results before and after 
adapting Total Mesorectal excision techniques. TME resulted in significant 
reduction of local recurrence and increase in survival. 
Tumors of middle and lower third of Rectum need Total MesoRectal 
excision. In case of upper rectal tumors mesorectal excision should be 
done 5cms below the lower border of the tumor, which may cause 
ischemia of the Anorectal stump and likely to result in anastomotic leak, 
which needs covering stoma in patients undergoing TME. TME has 
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reduced local recurrence rates and improved survival, sharp dissection per-
formed in the areolar tissue behind the mesentery, in front of the sacrum 
and at the level of Waldeyer fascia. Fascia propria should be intact with 
proper rectal dissection; total mesorectal excision is done for cancers of the 
distal rectum for which APR or low anterior resection and coloanal 
anastomosis.  
More proximal rectal cancers, use a margin of approximately 4 cm 
of distal mesorectum because tumor deposits in the mesorectum are rarely 
reported 4 cm beyond the tumor 
ROLE OF LATERAL PELVIC LYMPHNODE DISSECTION(34) 
Rectal cancers tumor spreads laterally to obturator, hypogastric and 
nodes along iliac vessels and upwards along superior rectal and inferior 
mesenteric vessels. 
Positive mesorectal nodes associated with high local recurrence rate. 
Extended resection results in poor quality of life as the pelvic autonomic 
nerves are sacrificed during lateral lymph node dissection.  
Autonomic nerve preservation procedures were developed resulting 
in improved urinary function. Morita5 et al in 2003 has shown that overall 
recurrence-rate was only 6.3 % and five year survival was 47 %.after 
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lateral lymph node dissection, the prognosis of patients with pelvic 
autonomic plexus involvement was unfavorable. 
Outcome between adjuvant chemoradiotherapy and lateral pelvic 
lymph node dissection following total mesorectal excision for  middle 
rectal tumors  is studied by Jin C Kim et al6  No difference in disease free 
survival(67.3% vs 68.6 %).or  overall survival (78 % vs 73.9% ) Loco 
regional recurrence rate was 2.2 fold higher in  lateral lymph node 
dissection group (16.7 % vs7.5 5 ,p = 0.044 ).  
Addition of lateral lymph node dissection to total mesorectal 
excision prolonged operative time and increased the transfusion, concluded 
that even after lateral lymph node dissection, postoperative 
chemoradiotherapy needed to decrease local recurrence. 
High incidence of loco regional and distal recurrence in locally 
advanced rectal cancers noted following surgical treatment.  Other 
neoadjuvant and adjuvant Treatment modalities tried to improve results. 
Patients with rectal cancer can be divided into three main groups. 
Most are resectable cancers, borderline resectable disease, (breached 
circumferential margins as predicted by imaging studies.), fixed 
unresectable cancers. 
 11 
 
Unresectable group – ends in leaving tumor within the pelvis,after 
chemoradiotherapy turn  resectable. Residual microscopic disease can 
persist after surgery at resection margins, within lymph nodes, or in distant 
metastatic sites in resectable cancers. The incidence of micro metastases in  
lymph nodes T1 -12%, T2-22%  and T3,T4-58% .In locally advanced 
rectal cancer  lymph node involvement and positive resection margin 
leading to local recurrence and metastatic disease. To improve local 
control and overall survival (OS) chemotherapy  and radiotherapy  used as  
adjuvant therapy to eradicate cells at the margins or in discontinuous areas 
of tumor within the pelvis, in nodes, or in distant metastatic sites.   High 
risk for local recurrence and poor survival reported with preoperative 
radiotherapy alone in borderline unresectable cancers, which emphasizes 
the need for combining trimodality therapy .Chemotherapy as a component 
of chemoradiotherapy, act as a radio sensitizing agent and eradicate distant 
micro metastases and it is investigated with different agents in a number of 
trials. 
CHEMOTHERAPEUTIC  DRUGS 
Fluropyrimidines  
5-FU - an inactive drug, converted to 5-fluorouridine-5′-triphosphate 
(FUTP), by serial reactions and then incorporated into RNA, where it 
interferes with RNA processing and mRNA translation.  
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5-FU, resulting in inhibition of DNA synthesis and function.  
5-FU is administered intravenously& clinical activity of this drug is 
highly schedule-dependent. It has short half-life, on the order of 10–15 
minutes, infusional schedules favored over bolus schedules. 
Toxicity  
Myelosuppression  
Diarrhea  
Nausea and vomiting 
Neurotoxicity  
Skin toxicity by the hand-foot syndrome.  
CAPECITABINE 
• a fluoropyrimidine carbamate prodrug with 70–80% oral 
bioavailability  
• converted to its active form in tumor 
• side effects Diarrhea and the hand-foot syndrome 
myelosuppression, nausea and vomiting, and mucositis-less 
than infusional 5FU  
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PLATINUM ANALOGS  
Cisplatin  
• kills tumor cells in all stages of  cell cycle and bind DNA 
leading to inhibition of DNA synthesis and function. 
• bind to both cytoplasmic and nuclear proteins, contribute to 
their cytotoxic and antitumor effects 
• Platinum complexes appear to synergize with other anticancer 
drugs-5FU  
• extensively cleared by the kidneys and excreted in the urine, 
needs dose modification in renal dysfunction 
• Oxaliplatin –preferred as first line drug with 5FU and Folic 
acid  
• Toxicity is reversible neurotoxicity. 
Role of preoperative radiotherapy 
On administering preoperative radiotherapy the size of primary 
tumor and the number of nodes involved are reduced. The extent of 
pathological down grading of tumor achieved varies with the dose of 
radiation used, proved by MRC32 trial in 1984, significant reduction of 30 
% of number of nodes involved and negative nodes after a fractionated 
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irradiation of 20 Gy, but no difference was observed between control 
group and which received a single dose of 5 Gy. Preoperative radiotherapy 
also reduces local recurrence. It helps in reducing the size and extent of 
local spread and makes locally advanced tumors operable, associated with 
high toxicity and delay in abdominal and perineal wound healing. 
 No improvement in overall survival compared to surgery alone. 
Aim of extensive study in Preoperative radiotherapy was improving local 
control   
In 1974 Steams.et al7 reported on the results in the trial of 
preoperative radiotherapy, in Memorial Sloan Kettering Cancer Centre in 
New York. Patients were randomized to receive 20 Gy of preoperative 
radiotherapy or surgery only. No improvement in local recurrence or 
overall survival was noted. 
The Veterans administration Oncology Group (VASOG) had 20 Gy 
given preoperatively for two weeks followed by surgery. Additional 5 Gy  
if tumor was within five cm of anal verge.  There was reduction in number 
of nodes involved after irradiation and down grading of the tumor. 
Reduction in local recurrence after radiotherapy noted. 
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 Swedish Rectal cancer group27 -short course of radiotherapy 
studied extensively. 25GyRT over 5 days in 5 fractions followed by 
surgery in 7 days improved overall survival and decreased local recurrence  
• Follow-up  (13 years) - hypo fractionated radiotherapy 
resulted in improved overall survival-from 30%- 38% with 
short course therapy  
• Improved local recurrence rate from 26%to 9%.Cancer 
specific survival from 62%-to 72%   
Role of Radiotherapy in unresectable Rectal cancer 
 If CT shows unresectable tumor, preoperative radiotherapy in 
combination with chemotherapy or alone is recommended. Preoperative 
radiotherapy for locally advanced tumors using doses of 45-50 Gy is 
capable of down staging without chemotherapy. The 5-year survival rate 
was only 18% after complete resection, and these patients continued to 
have local failure. 
 Patients have even poorer overall median survival duration of 8-10 
months who remain unresectable after radiotherapy  
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Unresectable Rectal Cancer 
Randomized Trials of Chemoradiotherapy versus Radiotherapy. In a 
single small phase III randomized study, fixed inoperable rectal cancer in 
70 patients were treated.  Chemoradiotherapy delivered methotrexate,  
5-fluorouracil and folinic acid in combination with hyperfractionated split-
course to total dose of 40 Gy over 8 weeks.  The trial showed an advantage 
in terms of local control and resectability for the chemoradiotherapy arm.  
 5-year survival rates were 18% versus 29% (nonsignificant) for 
radiotherapy versus chemoradiotherapy.  Local recurrence-free survival 
rates at 5 years - 35% versus 66% (p.03). These data support the view that 
chemoradiotherapy is more effective than radiotherapy.  For patients with 
T1N0 or T2N0 rectal cancer intensification of the chemoradiotherapy 
component achieves a higher pathological complete response, without a 
longer overall survival.  The risk for metastatic disease predominates and 
very low levels of local recurrence are achieved in this group of patients. 
Facilitating Sphincter-Sparing Procedures 
Bulky anterior tumors in obese men and low rectal cancers (3-6 cm 
from the anal verge) with a narrow pelvis has technical difficulty in 
surgery  if sphincter-sparing surgery  is the aim . Tumor shrinkage back 
from the distal margin and further sphincter-sparing surgery is achieved by 
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long course chemoradiotherapy followed by a planned delay prior to 
surgery. 
Phase II studies with chemoradiotherapy showed impressive results 
and an excellent outcome if marked shrinkage of the distal tumor margin is 
seen on long term follow-up 10% 11 or even a 20%12 higher chance of 
overall sphincter-sparing surgery achieved, which is shown in Subset 
analysis of randomized trials with preoperative CRT (10). 
Sphincter-sparing surgery depends on many factors experience:   
 Accessibility, Tumor size, Location surgical training and the 
individual’s philosophy regarding risk and experience.  
A randomized trial with short course radiotherapy against 
preoperative chemoradiotherapy with the endpoint of sphincter-sparing 
surgery showed no difference13, surgeons (Polish Colorectal Study Group) 
tested neoadjuvant chemo radiation to short-course preoperative radiation 
(25 Gy in five fractions) in resectable clinically staged T3 and T4 tumors, 
To chemoradiation -5040 cGy  at 180 cGy per fraction with chemotherapy 
(5-FU 325 mg/m2/day and  leucovorin 20 mg/m2/day given as rapid 
infusion on 5 consecutive days during weeks 1 and 5 of radiotherapy) 
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 Adjuvant chemotherapy was optional. Acute toxicity and local 
recurrence were high in chemoradiation arm (18.2Vs3.2 & 9%Vs 14.2%).   
No significant difference in, disease free survival, overall survival or late 
toxicity.  
Preoperative chemoradiotherapy versus Postoperative 
chemoradiotherapy  in Resectable Rectal Cancer 
A randomized trial compares postoperative chemoradiotherapy with 
preoperative chemoradiotherapy. 
 Three trials in this setting - the National Surgical Adjuvant Breast 
and Bowel Project (NSABP) R03, German CAO/ARO/AIO-94 trial the 
intergroup trial INT-0147 
National Surgical Adjuvant Breast and Bowel Project Protocol R-0314  
 To determine preoperative chemotherapy and radiation therapy in 
the management of operable rectal cancer. Patients with primary operable 
rectal cancer were randomized to multimodality therapy after curative 
surgery or preoperatively. All patients received seven cycles of 5- 
fluorouracil (FU)/ leucovorin (LV) chemotherapy. The preoperative arm 
(Group 1) received the first three cycles of chemotherapy and all radiation 
therapy (5,040 cGy) before surgery, and four cycles of chemotherapy post 
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operatively. The postoperative arm (Group 2) received all chemotherapy 
and radiation after surgery. 5- Fluorouracil and leucovorin chemotherapy 
was given during the first and fifth week of radiation therapy. Primary 
study end points - overall survival and disease-free survival. Secondary 
end points included tumor down staging, primary tumor response to 
combination therapy, local recurrence and sphincter preservation.  
Overall treatment-related toxicity was similar in both groups. No 
patient was inoperable due to progressive local disease. In both groups use 
of protective colostomy in patients undergoing sphincter-sparing surgery 
and perioperative complications in surgical patients were similar.  
Evidence of tumor down staging in evaluable patients undergoing 
preoperative therapy, with 8 % of Group 1 patients had a pathologic 
complete response. 
Preoperative chemotherapy and radiation therapy regimen used were 
tolerable and safe as standard postoperative treatment, a trend to sphincter 
preservation and tumor down staging in the preoperative arm. This trial 
was closed prematurely due to poor accrual. In Preoperative 
chemoradiation group statistically significant improvements in disease free 
survival at 5 years (64.7%---53.4%) and better overall survival at 5 years 
(74.5%---65.6%). 
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NSABP-R-04 trial-14  
Primary end point-    local tumor control. It compared preoperative 
use of infusional 5FU with or without Oxaliplatin    to       Capacitabine 
with or without Oxaliplatin.  
No difference in complete pathological response, sphincter 
preservation or overall staging. Toxicity is more with Oxaliplatin 
containing regimes and addition of oxaliplatin did not improve clinical 
outcomes.  
Phase III trial Capacitabine Vs 5FU  
Chemoradiation in neoadjuvant arm  showed significant difference 3 
year survival  in Capacitabine arm(75.2% Vs 66.6%)   and 5 year overall 
survival 75.7% for capacitabine arm,66.6% for 5FUarm,  which supports 
the use of capacitabine  with radiation therapy.  
Intergroup trial INT-0147  
After randomizing only 53 patients, Intergroup INT-0147 trial 
closed early because of poor accrual.  
The planned RT dose was 50.4 Gy. 
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The German CAO/ARO/AIO-94 Trial (12,24 ) 
The German CAO/ARO/AIO-94 study 1995, for stage II/III 
resectable rectal cancer.  To investigate preoperative 5-FU-based 
chemoradiotherapy versus postoperative combined- modality treatment   
The primary endpoints were disease free survival, overall survival, and 
loco regional and distant control.  The secondary endpoints included the 
rates of curative (R0) resections, toxicity, sphincter- sparing surgery and 
surgical complications. (12) 
Preoperative chemoradiation with 5040 cGy in 28 fractions along 
with PVI 5-FU (1000 mg/m2/day over 120 hours during weeks 1 and 5 of 
radiation) and postoperative chemotherapy (four 5-day cycles of 5-FU) or 
postoperative chemoradiation that differed only by the addition of another 
540-cGy boost. Total mesorectal excision (TME) was performed either 
within 6 weeks after preoperative treatment or was followed by adjuvant 
treatment 1 month postoperatively. The primary outcome of OS did not 
differ significantly at 5 years -preoperative (76%) and postoperative (74%) 
groups. Local recurrence improved to 6% compared to 13% at 5 years (P = 
0.006).  Preoperative delivery improved the rate of any acute grade 3 or 4 
toxicity from 40% to 27% (P = 0.001) & late toxicity from 24% to 14%  
(P = 0.01) 39% in the preoperative group –underwent a sphincter-
preserving approach, versus 19% in the postoperative group (P = 0.004).  
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Preoperative approach is the preferred method because of improved 
local control, better toxicity profile and improved sphincter preservation 
for low-lying tumors. The locoregional failure rate was 13% for the 
postoperative arm.  
Preoperative chemoradiotherapy -6%,  Overall survival rate and 
Disease free survival was greater in the preoperative arm.   for those 
patients, initially felt to have  abdominoperineal excision slightly higher 
sphincter-sparing surgery rate was noted.  In addition, compliance 9 2 % in 
the preoperative arm and was low for the postoperative arm, and only 54% 
received the full radiotherapy dose. 
 Acute and late toxicities - less frequent in the preoperative arm, 
Patients in the postoperative arm would have received a 10% higher 
radiotherapy dose (5.4-Gy radiation boost in the postoperative arm). 
Because of the constraints of acute and late toxicities Radiotherapy dose 
escalation has rarely been evaluated in rectal cancer.  
The Lyon R 96-02(16) study used contact therapy with an extra 8.5 
Gy in three fractions to boost external beam radiotherapy.  Higher 
complete clinical response rate and a higher sphincter-sparing surgery rate 
are seen. No difference in overall survival or loco regional failure or 
overall survival at 2 years , even with Dose escalation prior to surgical 
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resection which is illogical to improve local control. If surgery can achieve 
a good quality mesorectal excision, then recurrences are likely to lie 
outside.  Higher rate of acute toxicity seen with dose escalation of 
radiotherapy.    
In 1984, the    EORTC  study -two-arm randomized clinical trial to 
compare the efficiency of radiotherapy alone before radical surgery  with 
preoperative administration of radiotherapy with 5- fluorouracil .( 247 
patients )Total tumor dose of 34.5 Gy in 15 fractions of 2.3 Gy each (over 
an overall period of 18 days)'. Patients receiving combined preoperative 
therapy had intravenous 5-FU injection in the dose of 10 mg per kg of 
body weight (375 mg/m2) during the first four days 4 to 6 hours prior to 
irradiation. Surgery usually followed within 2 weeks after the last 
irradiation. 
The trial established an advantage in terms of local control and 
resectability for the chemoradiotherapy arm - a marginal statistical 
significance of P=0.06. Combined modality arm had a higher postoperative 
death and incidence of side effects it had a greater effect in controlling the 
disease process, mainly distant metastases to the liver. No difference was 
observed in local recurrence. Though not statistically significant Disease 
free survival was longer in the combined modality group. 
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The incidence of deaths due to malignancy was higher in the 
radiotherapy alone group.   And nonmalignant and intercurrent deaths were 
higher in the combined modality group. The authors concluded that side 
effects and intercurrent deaths can be effectively reduced by observing 
with adjuvant therapy and more stringent selection in disease and patients' 
criteria, 
EORTC 22921 Trial 17,18 
In 1993 The EORTC 22921 trial was enrolled 1,011 patients with 
T3/T4 resectable rectal cancer  
With endpoints of disease free survival and overall survival 
 Patients were allocated to the following four arms:  
Arm 1, preoperative radiotherapy 45 Gy in 5 weeks; 
 Arm 2, preoperative radiotherapy plus two 5-day chemotherapy 
courses  (fluorouracil 350 mg/m2 /d and leucovorin 20 mg/m2 /d) in the 
first and fifth week of radiotherapy; 
 Arm 3, preoperative radiotherapy plus four postop chemotherapy 
courses and  Arm 4, preoperative radiotherapy and chemotherapy plus 
postoperative chemotherapy. 
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Role of the duration and timing 
 Of 5-FU-based chemotherapy both in combination with 
preoperative radiation therapy, and in the postoperative adjuvant setting 
are tested. The trial stratified according to T stage, distance to the anal 
verge, sex.  
Total mesorectal excision (TME) was only recommended in 1999. (2)  
Compliance with the preoperative chemotherapy was high, only 
42.9% adhered to the postoperative component of chemotherapy. The 
addition of preoperative chemotherapy to radiotherapy caused significant 
downsizing (p< 0.001), down staging (p < 0.001), smaller number of 
examined lymph nodes, less frequent lymph vascular invasions18. Toxicity 
was higher in the chemoradiotherapy arm.  
Complete pathological response rate was higher in the 
chemoradiotherapy arm and higher sphincter-sparing surgery rate was 
offered only a marginal benefit ( 55.6 % versus52.4%; p .05 ). At 5 years 
the loco regional failure rates were 17% with radiotherapy and 8% with 
chemoradiotherapy. 
 65.2% is the 5 year survival rate for both groups and no significant 
difference seen in disease free survival or overall survival between groups. 
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A major conclusion of the study 5FU based chemotherapy when 
combining with radiotherapy confers advantage in local control  
Federation de Francophone de Cancerologie Digestive -FFCD 9203 
Trial19 
 733 patients were randomized in the FFCD 9203 trial19 with T3/T4 
resectable rectal cancer, between pre-operative radiotherapy and 
preoperative chemoradiotherapy to a dose of 45 Gy. The same 
chemotherapy regimen (5-FU, 350 mg/m2, and folinic acid). overall 
survival was the primary endpoint.     Patients received postoperative 
adjuvant chemotherapy and compliance was70% Compliance in the 
preoperative chemoradiotherapy arm was 93%. 
The rate of grade 3 or 4 acute toxicity higher in the chemotherapy 
arm (14.6%, versus 2.7% for radiotherapy alone; p<.05).  Complete 
sterilization of the operative specimen more in chemoradiotherapy(11.4% v 
3.6%; P <.05) 
5year local recurrence is low in combined modality group (8.1% Vs 
16.5% P<.05). Overall survival, Sphincter preservation   and surgical 
complications were similar in two arms.         
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A similar number of patients in each arm developed metastatic 
disease (99 following radiotherapy and 107 following chemoradiotherapy). 
Treatment with TME reduced the local recurrence rate to 14% for 
radiotherapy alone and 5% for chemoradiotherapy from 1999 
The Polish Trial 13,30,35 
 316 patients randomized between preoperative conventional 
chemoradiotherapy (50.4Gy in 28 daily fractions with 5-FU and folinic 
acid and short course preoperative radiotherapy.  
Aim - Evaluation of sphincter-sparing surgery in short course five 
fractions of radiotherapy and immediate surgery   with long course 
chemoradiotherapy with an interval.  The main endpoint was Sphincter-
sparing surgery. Long fractionation chemoradiotherapy regimen has been 
directly compared with short course preoperative radiotherapy for the first 
time.  Complete pathological response rate was1% in the short course 
preoperative radiotherapy arm, 15% in the chemoradiotherapy arm. No 
impact on sphincter preservation 61% in the short course preoperative 
radiotherapy versus 58% in the chemoradiotherapy  (p=0.57).   
A circumferential resection margin of 1 mm was observed in13% 
after short course preoperative radiotherapy and 4% after 
chemoradiotherapy .  
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 Local failure rate 14.2% in the chemo radiotherapy versus 9% after 
short course preoperative radiotherapy 
No difference seen in overall survival and disease free survival   
In the recent European randomized trials to neoadjuvant 
radiotherapy  addition of 5-FU based chemotherapy led to overall survival 
• Tumor down staging Significantly better  
• Pathological complete response 
• Better local control  
•  No Longer- overall survival, disease free survival, and a 
higher chance of sphincter preservation  
• Significant problem remains with metastatic disease. 
 Adding a second drug (mitomycinC, oxaliplatin, or irinotecan) 
results in a higher pathological complete response rate, and more effective 
in killing micro metastases, but longer disease free survival and overall 
survival is not demonstrated. 
Dutch Colorectal Cancer Group. Kapiteijn etal 24 
Short term RT (25Gy in 5 fractions) with TME Vs short term RT 
(25Gy in 5 fractions) 
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• At 2 years in both arms overall survival was 82%,  
• Radiation improved the local failure rate at 2 years for 
patients in macroscopic tumor removal from 8.2% to 2.4% (P 
= 0.01).  
• Long term follow-up(12 years) showed 10 –year survival 
improved  in Stage iii CRM negative  receiving surgery and 
RT(50%) than surgery only (40%--P.032) 
Oxaliplatin added trials-   STAR-01, NSABP R-04, ACCORD12 
and CAO/ARO/AIO-04.  
STAR-01 (52) - primary end point – overall survival (infusional 5FU/RT - 
With / Without Oxaliplatin)  toxicities of grade ¾ are more in oxaliplatin 
arm (24%Vs 8% P<.001 )  
NSABP R-04 trial -primary end point is local tumor control 
complications are common after Oxaliplatin addition.  CAO/ARO/AIO-04 
53 initial reports revealed significant complete pathological response (17% 
Vs13% P =.038%) rates in oxaliplatin arm due dose variation of 5FU 
regimes 
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CAPACITABINE /RT- with/without OXALIPLATIN TRIAL- 
ACCORD12 /0405 Prodige 2 Trial 54 – Primary end point 
pathologic complete response,       Toxicities are more with oxaliplatin 
arm25%Vs 11%,   
Complete pathological response 19.2% in oxaliplatin added arm Vs 
13.9,  Minimal residual disease -39.4 % in Oxaliplatin arm Vs 28.9%.   In 
neoadjuvant chemoradiation - addition of oxaliplatin   not recommended. 
ARISTOTLE TRIAL55 
A phase III randomized trial in MRI defined locally advanced rectal 
cancer, using Standard Vs Novel chemo radiotherapy as preoperative 
treatment. 
 Aim- improves outcome after addition of second drug to 
chemotherapy regimen  
UK based multicenter, prospective, double arm study with disease 
free survival as primary end point & secondary end point-disease specific 
survival, overall survival, loco regional failure, CRM margins, 
histopathological complete tumor response, surgical morbidity, quality of 
life, tumor cell density. 
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Study using addition of Irinotecan to standard Capacitabine based 
regimen, ARM-A-Capacitabine 900mg twice daily for 5 days weekly for 5 
weeks along with 45Gy RT in 25 fractions.  ARM B –Irinotecan 60mg 
once weekly for 4 weeks with oral Capacitabine 650 mg twice daily 5 days 
weekly with RT 45Gy in 25 fractions.  The study is not yet approved. 
EXPERT-C Trial addition of CETUXIMAB to Capacitabine 
/Oxaliplatin/RT.    Primary end point-complete response. Improved overall 
survival rate is noted in KRAS wild type tumors 
INDUCTION CHEMOTHERAPY- 
GCR -3 trial before chemoradiation and resection a course of 
neoadjuvant chemotherapy –Cape OX regime –—induction therapy is 
tolerated and  less toxic.  
AVACROSS study (phase ii study) 
Addition of Bevacizumab to induction chemotherapy the regime is 
well tolerated and complete pathological response 36%, this study is not 
approved and it is investigational currently.              
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MATERIAL AND METHODS 
This study was conducted in the Department of Surgical 
Gastroenterology, Rajiv Gandhi Government General Hospital, Madras 
Medical college, Chennai. 
Study period 
From March 2012 to February 2014 
Eligibility Criteria 
• All patients with locally advanced operable rectal cancer i.e. 
T3, T 4, node positive tumors without distant metastasis 
• Patients with histologically confirmed adenocarcinoma within 
12 cm from anal verge(locally advanced  growth in Middle 
and Lower third ) 
• Patients  underwent sigmoid colostomy for intestinal 
obstruction 
• Patients -Lower third Rectal growth with upper Anal canal 
involvement 
• Radiological evidence of mesorectal invasion  
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Exclusion Criteria 
• Patients who previously had cancer other than basal cell 
carcinoma of skin 
• Patients who had received radiotherapy or chemotherapy  
• Contraindications to chemoradiotherapy 
• Tumor involving pelvic side walls, upper sacral vertebra, 
involving upper rectum 
• Distant metastasis.  
• Patients with poor performance status  
Medical ethics committee of the hospital approved the study. 
Preoperative evaluation 
After obtaining informed written consent from patients, enrollment 
into the study done. Loco regional staging done with contrast enhanced CT 
of abdomen and pelvis, Endorectal ultrasound and cystoscopy in cases 
suspected of bladder invasion. 
 A lymph node metastasis of four or greater than four as detected by 
imaging was staged as N 2 disease. Distant metastasis was excluded by 
contrast enhanced CT of abdomen and pelvis, chest X-ray and if necessary 
a CT chest. Colonoscopy was done to rule out synchronous lesions. 
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A basic work up including complete hemogram, Renal function 
tests, Liver function tests,  Tumor markers –CEA, Pulmonary function 
tests and Cardiac tests – ECG &Echocardiogram was done to rule out any 
major illness and to confirm the patient’s fitness for surgery. 
Treatment 
Preoperative external beam radiotherapy was given for a total dose 
of 50.4 Gy in 28 fractions of 180 cGy each, five times per week for total 
duration of five and a half weeks. It was given as anterior and posterior 
opposed portals using Telecobalt machine of 1.33 meV. The radiotherapy 
was given to include the tumor area and its drainage lymph nodes (pelvic-
internal, external iliac, obturator).  
The upper margin of radiotherapy field was L 5-S 1. The lower 
margin was obturator foramen, 1.5 cm below lower border of pubic 
symphysis. The lateral margin was 1 cm lateral to true pelvis at level of 
mid inguinal point. If the tumor extended to anal canal, inguinal nodes 
were included in the field; laterally the radiotherapy field was extended to 
anterior superior iliac spine. 
The chemotherapeutic agent used was 5 Flurouracil, used as a bolus 
of 350mg/m2 /d for 5 days, during the first and fifth weeks of radiotherapy 
along with 20mg/m2 of leucovorin. Postoperatively 5 Flurouracil was 
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given for four cycles (350mg/m /d, once in four weeks five times weekly) 
started postoperatively four weeks after surgery. 
Surgery 
Patients were assessed five weeks after surgery regarding the 
response to treatment - -either regression or progression of the disease by 
clinical as well as by radiological methods. 
 Decision for abdominoperineal excision of rectum, an anterior 
resection or pelvic exenteration was made preoperatively and modified 
according to the peroperative findings. 
According to the standardized technique Total mesorectal excision 
was done. All patients who underwent anterior resection had a protective 
ileostomy. Patients with unresectable growth due to locally advanced 
disease had colostomy only. 
During therapy, for signs of acute toxic effects requiring change in 
dosage or regimen patients were monitored weekly. 
According to the Radiation Therapy Oncology Group criteria -Acute 
and long term toxic effects were graded with respect to acute and late 
adverse effects of radiotherapy. Patients were observed for Peroperative 
and postoperative complications   which included bleeding, ileus, intestinal 
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fistulas, intra-abdominal abscess, perineal wound complications, urinary 
retention and death. 
Follow up 
Patients were followed at three monthly intervals for two years.  
Evaluations consisted of History and physical examination, a Complete 
blood count and Liver function tests and Renal function tests, Tumor 
marker -CEA, Proctoscopy, Abdominal ultrasonography, CT of Abdomen 
and Chest radiography (annual).  
Local recurrence was to be confirmed histopathologically or by 
sequential radiological studies to detect mass lesion. Distal recurrence was 
confirmed histopathlogically. 
All resected specimens were examined for histological grade, degree 
of fibrosis, resected margin status and nodal status. The primary end points 
analyzed were downsizing of tumor, down staging of the tumor, sphincter 
saving rates, toxicity of chemoradiotherapy, and patient compliance for the 
regimen. Secondary end points analyzed were the incidence of local 
recurrence, distal metastasis. Downsizing was defined as a reduction in the 
size of tumor after chemoradiotherapy as determined by physical 
examination.  Down staging was defined as decrease in TNM stage, as 
assessed after chemoradiotherapy in the surgically resected specimen.  
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RESULTS 
From March 2012 to February 2014, in the study fifteen patients 
were enrolled.  chemotherapy given to all the patients as inpatient after 
prior complete hemogram examination. Radiotherapy given to the patient 
as inpatient or as outpatient admitted in the hospital whenever they 
developed complications, all the patients were periodically reviewed in our 
outpatient clinic and reported after completion of chemoradiotherapy. 
Fifteen   patients underwent surgery after neoadjuvant chemoradiotherapy. 
Bleeding per Rectum is the predominant symptom. Their demographic 
characters are presented below.  
Age Mean 58.4 yrs 
 Range 37-73 yrs 
Sex Male 11(73%) 
 Female 4 (27%) 
 
Patients’ age ranged from 37-73 years, mean age being 58.4 years. 
Eleven were males and four were females. Part of the tumors extended into 
anal canal from lower third of rectum into upper anal canal (20%). Nine 
patients had tumors involving lower rectum and Three had tumor involving 
middle third of Rectum. 
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Histology Type No (%) 
Well differentiated 10 (66.66%) 
Moderately differentiated 4(26.24%) 
Poorly differentiated 1(6.66) 
 
Tumor Characteristics 
Clinical Stage of       Tumor No ( % ) 
Stage I ( T1,T 2, NO,MO ) 0 
Stage 2 A ( T3, NO, MO ) 3(20%) 
Stage 2 B ( T4, NO, MO ) 1(6.66 %) 
Stage 3 A ( Tl, T2, Nl, MO ) 0 
Stage 3 B ( T3, T4, Nl, MO ) 9(60 %) 
Stage 3 C ( any T, N2, MO ) 2 (13.32 %) 
Stage 4 (any T, any N, M 1) 0 
 
Surgical data 
Interval to CRT and  Surgery 
( in weeks) 
No of cases 
5 0 
6 14 
7 1 
8 0 
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Surgery Performed Number 
Anterior resection 5(33.33%) 
APER 10(66.66%) 
 
Fourteen patients underwent surgery at six weeks after 
chemoradiotherapy; one patient had surgery after seven weeks in post 
chemoradiotherapy period. Five patients underwent anterior resection, 
none of the female patients had uterine or bladder involvement which was 
noticed in preoperative imaging as well as intra operative assessment. Ten 
patients underwent abdominoperineal resection. Patient with growth 
extension up to pelvic side wall which were inoperable were not included 
in the study and the patients were offered palliative sigmoid colostomy and 
they were not included in the study 
Complications 
Peroperative complications 
Bleeding   
 
1 
        
Post operative complications 
 
 
Abdominal wound infection 
 
4 
 
Perineal wound infection 
 
3 
 
Intra abdominal abscess 
 
0 
 
Urinary retention 
 
2 
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Chemoradiotheray toxicity 3 (20 % ) 
Mild-Skin irritation & 2(13.32%) 
Discoloration  
Vomiting 2(13.32%) 
Diarrrhoea 1 (6.66 % ) 
Severe – Anaemia 1 (6.66 % ) 
 
One patient developed intraoperative bleeding due to injury to sacral 
plexus. It was controlled by packing. Minor complications occurred in four 
patients, developed abdominal wound infection which was treated 
conservatively by Antibiotics after confirming the sensitivity by culture.  
One patient developed perineal wound gaping treated with thorough 
letting out the collection and thereafter with regular dressings. Two 
patients developed urinary retention in the postoperative period, was 
treated with continuous bladder drainage for one month. Fourteen patients 
in the series are treated by open approach; one patient underwent 
laparoscopic abdominoperineal excision of rectum. 
One patient developed anemia requiring blood transfusion after the 
second dose of chemotherapy in the fifth week. Minor complications like 
skin irritation occurred in two patients, vomiting in two, diarrhea in one 
which was self-limiting.  
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Results of Surgery 
Downsizing of Tumour 14/15 p 
Downstaging of Tumour 12/15 p 
Follow up Period 6 months-12 months (median- 9 months) 
Local recurrence Nil 
Distant metastasis Nil 
 
Downsizing of tumor seen in fourteen of fifteen patients who had 
responded well to neoadjuvant chemoradiotherapy. In twelve of fifteen 
(12/15) patients down staging occurred 
The follow up period ranged from six months to twelve months, 
with the median follow up period being nine months. No patient developed 
local recurrence. Distant metastases in the form of Liver metastasis not 
noted in any of the patients who had disease. 
APER intended Sphincter saving procedure 
12 2/15(13.32) 
 
Of the twelve patients who had been treated for   locally advanced 
carcinoma Rectum for whom APER was planned, a sphincter conservation 
surgery was possible in two of them after neoadjuvant chemoradiotherapy 
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and those patients underwent anterior resection. Before neoadjuvant 
chemoradiotherapy only three anterior resections were planned. After it, 
five anterior resections were done with covering ileostomy done to protect 
the anastomosis as well as to reduce leak related complications. 
Postoperative TNM staging 
(T1.T2.N0, MO) Stage 1 3 (20 % ) 
(T3,N0, MO) Stage 2 A 6 (20%) 
( T4, NO, MO) Stage 2 B 0 
( Tl, T2, Nl, MO ) Stage 3 A 2(13.2%)  
( T3, T4, Nl, MO ) Stage 3 B 4 (26.64 %) 
( any T, N2, MO ) Stage 3 C 0 
( any T, any N, Ml ) Stage 4 0 
 
Anterior resections intended Anterior resections done 
3(20%) 5 (33.3%) 
 
Neoadjuvant chemoradiotherapy increased sphincter conservation in 
2/15 patients in our study. 
Patient compliance 
Fifteen of the fifteen patients had completed the full course of 
chemoradiotherapy followed by surgery (100%) with minimal toxicities to 
chemoradiotherapy treatment. 
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DISCUSSION 
Over the last few years Significant advances are made in the 
colorectal cancer. Management is altered by more thorough understanding 
of the molecular basis for this disease, coupled with the development of 
new therapeutic approaches and expertise in management.  Approach in 
the workup and disease staging of the patients is altered by new strategies 
for screening and for the detection of recurrent disease by careful 
postoperative follow up. 
Preoperative Chemoradiotherapy 
The rationale for giving preoperative chemoradiotherapy is to 
improve the survival  and the advantage of delivering both the agents 
preoperatively. These advantages include improved compliance given 
before a major surgery in well vascularized setting to assist in down 
staging to enhance the rate of curative surgery, prevents tumor tract 
seeding at surgery by sterilizing the tumor field and permit sphincter 
preservation in low lying rectal tumors. Irradiation is more effective is 
better if given preoperatively due to better tumor oxygenation. 
The sphincter conservation rate also doubled after preoperative 
chemo radiotherapy. Postponing the surgery to six weeks help in shrinkage 
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of tumor and recovery of tissues after treatment before fibrosis sets in. 
Higher pathological complete response produced by addition of 5FU to 
preoperative radiotherapy over radiotherapy alone13 
No improvement in disease-free survival (DFS) or overall survival 
but Better locoregional control 
 About 30% patients develop distant metastases. 
   Due to Better pCR and loco regional control rates, 5- FU-based 
preoperative chemo radiotherapy followed by total mesorectal excision has 
become the standard of care in patients with locally advanced rectal 
cancer. 
Current chemoradiotherapy schedules have been empirically 
developed. More recently, oxaliplatin and irinotecan have been explored to 
increase tumor shrinkage prior to surgery  within chemo radiotherapy 
schedule, There is no widely accepted optimal timing,  schedule, sequence  
either in terms of the drugs or  RTdose. 
High levels of normal tissue damage, including small bowel injury, 
nerve dysfunction rectal bleeding, impaired Sphincter function, vaginal 
stenosis, , and sacral fractures  with  Radical pelvic RT at doses of 55-60 
Gy. 
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40-50 Gy in 1.8- to 2.0-Gy fractions Lower radiotherapy doses have 
become established as a standard, because it is associated with a good 
tumor response and with more acceptable levels of late morbidity. 
Downsizing of tumour 
Study Downsizing p value 
Polish Trial 13 2004 Present p <0.001 
German Rectal Cancer 
Study group12 2004 
Present p < 0.001 . 
EORTC trial 2292117 
2005 
Present p <0.001 
This study Present  
 
Neoadjuvant chemo radiotherapy helps significant downsizing of 
tumor as it causes tumor shrinkage. In this study downsizing occurred. 
This is almost in accordance with other studies which have shown similar 
significant regression of the tumor after chemoradiotherapy. 
 Downsizing is indicator of good response to preoperative 
chemoradiotherapy. This is concurrence with the results of Polish trial the 
tumor was 1.9 cm smaller in patients after chemoradiotherapy 
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Study Down Staging Percentage of patients 
downstaged 
Rich et al2U, 1995 Present 64 %p<0.01 
German Rectal Cancer 
Group Trial 12 2004 
Present 62 %p <0.001 
EORTC Trial 22921 17 
2005 
Present 52 % p < 0.001 
Chung Wah Lam et al 4 
2005 
Present 69 %p<0.01% 
This study Present  
 
After preoperative chemoradiotherapy, postoperative histopathology 
shows downgrading of the tumor. In this study of showed down staging (p 
<0.0001). A good pathological response is a good prognostic indicator, 
with patients having a good response having fewer incidences of improved 
overall survival and local recurrence l. Chung Wah Lam et al 4 in 2005 has 
shown that 69 % of his patients had decreased tumor stages after 
chemoradiotherapy. 
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Preoperative TNM Staging Vs Post-operative TNM Staging This 
Study 
Stage Preoperative TNM Postoperative TNM 
Stage 1 
 ( Tl,2, NO, MO ) 
0 
 
3 
Stage 2 A 
( T3, NO, MO ) 
3 6 
Stage 2 B  
( T4, NO, MO ) 
1 0 
Stage 3A 
(T1,T2, Nl, MO) 
0 2 
Stage 3B  
(T3, T4, Nl,MO) 
9 4 
Stage 3 C  
( any T, N2, MO) 
2 0 
Stage 4  
(any T, any N, Ml) 
0 0 
 
In this study preoperatively around 60% of the tumors were in stage 
3 B. Post-operative, histopathology showed a significant shift towards 
lower stages stage. 
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2A in 20% and 20 % in stage 1. Due to the tumoricidal effect of 
chemoradiotherapy the lymph node positivity was reduced. 
Effect of time interval on surgery and down staging 
Long time interval between radiotherapy and surgery led to 
sphincter preservation because of tumor down staging When the optimum 
time interval between radiotherapy and surgery was analyzed. 
In 1999 Francois et al, conducted a randomized trial to compare 
short interval outcome with long interval of 6-8 weeks. A long interval 
between preoperative radiotherapy and surgery was associated with 
pathologic down staging (10.3% in the SI group v 26% in the LI group, P 
.005) and  a significantly better clinical tumor response (53.1% in the SI 
group Vs 71.7% in the LI group, P.007) . No differences in morbidity, 
local relapse, and short-term survival noted between the two groups at a 
median follow-up of 33 months. 
Sphincter-preserving surgery was performed in 76% of cases in the 
LI group versus 68% in the SI group (p < 0.27).He concluded that a long 
interval between preoperative irradiation and surgery provides increased 
tumor down staging.  In  questionable sphincter preservation, a long 
interval may increase the chance of a successful sphincter- saving surgery. 
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The ideal time interval is 6 weeks (56, 21,28) for surgery after 
radiotherapy when there is an optimal tumor response and further delay 
does not enhance the effect of radiotherapy. When fibrosis sets in, 
dissection also becomes technically difficult with increased incidence of 
complications like intra-abdominal sepsis, increased bleeding. In this 
study, the interval ranged from 6 to seven weeks, median being six weeks.  
Sphincter Saving Procedures after neoadjuvant chemoradiotherapy 
Study Sphincter saving Percentage 
Rich et al20 1995 Present 66.6 % 
NSABP Trial 14 1997 Present 50 % 
Polish Trial 13 2004 Present 58 % 
German Rectal Cancer 
Group Trial 12 2004 
Present 39 % 
Chung Wah Lam et al 4 
2005 
Present 82 % 
This study Present 13.12 % 
 
One of the advantages of preoperative chemoradiotherapy is that 
tumor downsizing helps sphincter saving procedures. The incidence of 
sphincter saving procedures range from 39 % up to 82 %. In this study, 
preoperatively only three patients were planned for an anterior resection. 
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After neoadjuvant therapy, anterior resection was possible in five patients, 
sphincter conservation rates were increased. The lower number of 
sphincter saving procedures is due to the fact that most of the tumors (66.6 
%) had already extended into the anal canal, necessitating 
abdominoperineal excision of rectum. 
Distal Resection Margin after Neoadjuvant chemoradiotherapy 
Nearly 50% of patients undergo Abdominoperineal excision of 
rectum despite the increasing use of sphincter preservation for rectal 
cancers. In many circumstances, for adequate distal margins, 
Abdominoperineal excision of rectum is performed.  
 More limited distal margins may be appropriate as per evidence. 
For low lying rectal tumors doing an abdominoperineal excision does not 
increase the radicality of the procedure or improve survival. Study by Paty 
et al found that no increase in pelvic recurrence when the distal margin was 
<2 cm compared with >2cm.  1 cm distal margins are adequate as per 
recent evidence’22.  in the past, distal margins as great as 5 cm were 
advocated 
Smaller distal margins, even 1 cm, may be adequate, supported by 
pathological evidence that distal intramural spread rarely exceeds 1 cm .A 
number of clinical pathological studies 2 2 that examined distal intramural 
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spread suggest that. When significant distal spread does occur, long term 
survival is affected adversely, despite abdominoperineal excision of 
rectum. The presence of distal spread is associated with decreased survival 
due to recurrence  (mainly in lung). The use of centimeter and sub 
centimeter margins is controversial. 
Jose G Guillem et al 25 on prospective pathological analysis of whole 
mount sections of rectal cancer following combined modality therapy in 
109 patients has shown that intramural extension occurred only in 1.8 % 
patients (<0.95 cm ). Hence he concluded 1 cm margins are sufficient after 
preoperative chemoradiotherapy and this increases the chances of sphincter 
preservation without increasing the chances of local recurrence. 
Preoperative chemoradiotherapy also reduces circumferential 
resection margin positivity. Circumferential resection margin positivity is 
as high as 25 % if no preoperative chemoradiotherapy is used. In this study 
a distal margin of one cm did not result in margin positivity in any of the 
postoperatively examined specimens. 
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Local Recurrence 
 
Study 
Duration of follow 
up 
Local 
Recurrence 
Percentage 
EORTC Trial ^984 7 years Present 15 % 
Rich et al 20 1995 2 years,3 months Present 4% 
Polish Trial 13 2004 4 years Present 14.2 % 
German Rectal Cancer 
Group Trial 12 2004 
4 years Present 6% 
EORTC Trial 22921 17 
2005 
5.4 years Present 8 % 
Jean Pierre Gerard et al 
19
 FFCD 9203, 2006 
81 months Present 8.1 % 
This study 9 months Nil 0% 
 
Local recurrence  
 Tumor factors  
• Tumor invasion beyond muscle(T3 to T4)  
• Nodal involvement 
• poor  differentiation,  
• Mucin production and venous or lymphatic invasion.  
• CRM positivity 
• Intestinal obstruction,  
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• Tumor Perforation 
Tumor adherence to other local organs  
Molecular Features  
• Aneuploidy  
• Mutation in  p53 
• Loss of heterozygosity at chromosome 18q. 
•  microsatellite instability- poor  
Technical Factors  
Tumors in the distal rectum 
Locally extensive tumors are far more likely to recur than mobile 
tumors, which type of procedure is performed does not matter. Local 
recurrence is significantly higher in patients who have circumferential 
involvement than those without involvement. Recurrence is also influenced 
by site of lesion in rectum, lower one third tumors have higher incidence 
than upper third tumors. Incomplete removal of tumor is a very important 
cause for local recurrence 
Local recurrence ranges from 5.8% as reported by Kapitjein et al24 
to 15 %. TME considered as a contributing factor in reducing pelvic 
recurrences to as low as 5% to 8% in high-risk patients 
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Follow up of this study during a ranging from 6 months to 9 months 
and  no evidence of local recurrence is noted. This correlates well with the 
response to chemoradiotherapy and an adequate TME as evidenced by 
downsizing and down staging. 
  Quirke et al. demonstrated that radial spread into the mesorectum is 
a common occurrence. Sharp dissection along the parietal pelvic fascia 
ensures resection of   (5 mm) occult nodal metastases which may be left 
behind and causing local recurrence.  
Radial margins are a more important predictor of disease recurrence 
and survival than distal margins. 
There is an increased risk of recurrence for patients who undergo 
have abdominoperineal excision of rectum and reflects the worse prognosis 
attributed to tumors of the low rectum. The location of the tumor may be a 
more important prognostic factor. 
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 Toxicity of chemoradiotherapy 
Study Mild Toxicity (%) Severe Toxicity(%) 
German Rectal Cancer 
Group Trial 12 2004 
12 27 
EORTC Trial 22921 17 
2005 
38.4 13.9 
This study 26.66 6.66 
 
About 26.6 % of patients developed toxicity of chemoradiotherapy. 
Skin irritation and discoloration was the most common toxicity 
encountered. It was totally reversed after few weeks. This is comparable 
with other studies showing a range of 11 % to 15 %. The EORTC 22921 
trial showed a very high toxicity of 38.4 %. In this study no patient had a 
change in the chemoradiotherapy schedule due to toxicity. 
Postoperative complications 
Study Complications( %) 
German Rectal Cancer Group Trial 
12
 2004 
36 
EORTC Trial 22921 17 2005 22.8 
Jean Pierre Gerard et al 19 FFCD 
9203, 2006 
20.9 
This study 26.7 
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There is always a fear that neoadjuvant chemoradiotherapy increases 
preoperative complications, delays wound healing, and patients may need 
perineal flap cover to prevent post-operative wound disruption. The 
postoperative complications in this study were   26.7   % only. Of ten 
patients who underwent only on abdominoperineal excision of rectum only 
one developed perineal wound complication which was successfully 
treated conservatively. So preoperative chemoradiotherapy can be given 
safely with good patient compliance, minimal side effects and less 
postoperative complications.. 
Effect on survival 
With preoperative radiotherapy alone Randomized controlled studies 
have not shown any significant survival benefit. 
Jose G.Guilem et al(23) “ analyzed the long term outcome following 
preoperative combined modality therapy and total mesorectal excision of 
locally advanced rectal cancer,  estimated 10-year overall survival was 
58% and 10 year recurrence-free survival (RFS) was 62%. With a median 
follow-up of 44 months 
Lymph vascular invasion and/or perineural invasion (PNI), 
pathologic response of greater than 95%, and positive lymph nodes were 
significantly associated with disease free survival and overall survival.  
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CONCLUSION 
Neoadjuvant chemoradiotherapy given in stage 2/ middle and low 
rectal cancers causes significant downsizing, down staging of the tumor, 
increases the rate of sphincter conservation surgeries. 
 The toxicity of chemoradiotherapy is minimal, patient compliance 
is good. 
 The postoperative complications are not increased and it helps 
decrease the incidence of local recurrence. 
The effect on survival has to be determined on long term follow up 
only. Hence it is beneficial to administer it to patients with stage 2/3 
middle and low rectal cancers. 
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CASE REPORT FORM 
Name-    Age-    Sex- 
Address- 
Occupation (level)-  
H/o abdominal pain 
H/o Bleeding PR/ Mucus discharge   H/O Constipation  
H/o straining for stools and sense of incomplete evacuation 
H/o loss of appetite     H/o loss of weight 
H/o abdominal distension   H/o vomiting  
H/o fever      H/o comorbid illness  
DM, SHT,BA,TB,IHD   
General examination  
Respiratory system examination 
Cardiovascular system examination 
Abdominal examination 
Per Rectal examination 
Left supraclavicular node examination 
 
Investigations 
Complete blood count   Serum electrolytes 
Blood sugar     Renal function tests 
Urea      Serum creatinine 
Liver function tests   Bilirubin 
SGOT     SGPT 
SAP      Serum albumin 
Prothrombin time     
ECG 
Chest X-ray 
X-ray abdomen 
Echocardiogram 
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Ultrasonogram abdomen 
Barium enema 
Upper GI endoscopy 
Lower GI endoscopy 
CECT Abdomen and Pelvis  
Ostomy counseling 
Family counseling  
Informed consent including high risk procedure, postoperative ICU 
care for monitoring and ventilator support and resurgery in case of 
complications  
Type of surgical Procedure 
Outcome 
Wound infection 
Respiratory infection 
Anastomotic leak 
In hospital stay 
In hospital mortality 
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INFORMED CONSENT FORM 
 
Title of the study -“Analysis of Presentation, Management and outcome following 
Neoadjuvant therapy in Carcinoma Rectum” 
 
Name of the participant:  
of age and, exercising 
my free power of choice, hereby give my consent to be included as a participant in ___ 
____________________________________________ 
Name of the Principal/Co-Investigator: _________________________________ 
Name of the Institution: Department of surgical gastroenterology, Madras Medical 
College and Rajiv Gandhi government general hospital, Chennai. .I,________(name of 
participant), have read the information in this form (or it has been read to me). I was 
free to ask any questions and they have been answered. I am over 18 years. 
(1) I have read and understood this consent form and the information provided to me. 
(2) I have had the consent document explained to me. 
(3) I have been explained about the nature of the study. 
(4)  I have been explained about my rights and responsibilities by the investigator. 
(5) I have informed the investigator of all the treatments I am taking or have taken in 
the past ______ months including any native (alternative) treatments. 
(6) I have been advised about the risks associated with my participation in the study. 
(7) I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual   symptoms.  
(8) I have not participated in any research study within the past _____ month(s). 
(9) [I have not donated blood within the past _____months  
(10) I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in the hospital 
(11) I am also aware that the investigators may terminate my participation in the study 
at any time, for any reason, without my consent. 
(12) I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Government agencies, and ethics committee. I understand that they may inspect my 
original records. 
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(13) I understand that my identity will be kept confidential. 
(14) I have had my questions answered to my satisfaction. 
(15) I consent voluntarily to participate as a participant in the research study. 
     I am aware, that if I have any questions during this study, I should contact the 
investigators. By signing this consent from, I attest that the information given in this 
document has been clearly explained to me and understood by me. I will be given a 
copy of this consent document. 
For adult participants 
Name and signature / thumb impression of the participant (or legal representative if 
participant 
incompetent): 
(Name) __________________________(Signature)___________________ Date: 
__________   
Name and signature of impartial witness (required for illiterate patients):  
(Name) __________________________ (Signature)___________________ 
Date:__________  
Address and contact number of the impartial witness: 
______________________________ 
Name and signature of the Investigator or his representative obtaining consent: 
(Name) __________________________ (Signature)___________________ 
(Date)__________ 
 
 
Name and signature / thumb impression of the participant’s parent(s) (or legal 
representative 
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INFORMATION TO PARTICIPANTS 
Title: -  “Analysis of Presentation, Management and outcome 
following Neoadjuvant therapy in Carcinoma Rectum” 
Principal Investigator:  
Co-Investigator (if any): 
Name of Participant: 
Site:   
You are invited to take part in this research/ study/procedures/tests. The 
information in this document is meant to help you decide whether or not to take 
part. Please feel free to ask if you have any queries or concerns. 
What is the purpose of research?  Improved overall survival and decreased 
local recurrence rates have been achieved For locally advanced rectal cancers 
,with  neoadjuvant chemoradiation therapy (CRT) which leads to a decrease in 
tumor size and enhances the possibilities of tumor resectability and sphincter 
preservation These symptoms may last for ________(usual course of the 
disease). We want to test the efficacy and safety of a new _________ (drug / 
intervention / surgery /procedure/lab test) in this disease/condition. We have 
obtained permission from the Institutional Ethics Committee.  
The study design- Retrospective study   
Study Procedures The study involves evaluation of Carcinoma Rectum treated 
with neoadjuvant therapy for  which we will need tumor markers, barium enema 
colonoscopy, CECT abdomen  & pelvis. The planned scheduled involve visits at 
_____,_____,____,and______(days/ weeks) after your initial visit. You will be 
required to visit the hospital _______ number of times during the study.  
At each visit, the study physician will examine you. Some [blood / urine 
/imaging/clinical examination other] tests will be carried out at each visit. [… … 
ml of blood will be collected at each visit. Blood collection involves prick with a 
needle and syringe.] These tests are essential to monitor your condition, and to 
assess the safety and efficacy of the treatment given to you.In addition, if you 
notice any physical or mental change(s), you must contact the persons listed at 
the end of the document. You may have to come to the hospital (study site) for 
examination and investigations apart from your scheduled visits, if required.  
Possible risks to you –  If any, Briefly mention  
Possible benefits to you - If any, briefly mention  
 Possible benefits to other people  
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The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you will be 
allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like the 
Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You 
will be taken care of and you will not loose any benefits to which you are 
entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the 
right to withdraw from this study at any time during the course of the study 
without giving any reasons. However, it is advisable that you talk to the research 
team prior to stopping the treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                           Signature of Participant   
Date                                                                Date   
 
 
MASTER CHART 
No Name 
Age 
& 
sex 
Presentation 
Location of 
tumor 
Staging 
of 
tumor 
Comorbid 
Total dose of  
Radiotherapy 
(Gy) 
Number of 
fractions 
Chemotherapy 
Drugs 
surgery 
Duration of 
treatment 
1 LOGANATHAN 70/M Bleeding PR Lower 
Rectum 
T3 N2 M0 HT 50.4 28 5 FU 
Cisplatin 
APER 4 MONTHS 
2 MANOHARAN 58/M Bleeding PR Middle & 
Lower 
Rectum 
T3NX M0 HT 50.4 28 Cisplatin Low Anterior 
resection 
3.5 months 
3 BALASUBRAMANIAN 63/M Altered bowel 
habits 
Lower 
rectum 
T4a 
N0M0 
- 50.4 28 5fu 
cisplatin 
APER 4 Months 
4 PARTHASARATHI 53/M Bleeding PR Lower 
Rectum 
T4A N1 
M0 
- 50.4 28 OXALIPLATIN 
CAPACITABINE 
APER 3.5 Months 
5. VELLAIKANNU 73/M Bleeding PR Lower 
Rectum 
T3N2M0 - 50.4 28 OXALIPLATIN 
CAPACITABINE 
Low Anterior 
Resection 
6 months 
6 MANGAMMAL 65/F Bleeding PR Middle 
rectum 
T3N1M0 - 50.4 28 CISPLATIN  
5FU 
Anterior resection 6 months 
7  SIVA SANKARI 38/F Bleeding PR Middle third 
rectum 
T3N1M0 - 50.4 28 CISPLATIN  
5FU 
Anterior Resection 6 months 
8 VAITHYALINGAM  68/M Bleeding PR Lower 
Rectum 
T3N1M0 HT 50.4 28   CISPLATIN  
5FU  
APER 4 months 
9 RAVI  48/M Constipation Lower 
Rectum 
T4a N1 
M0 
- 50.4 28  CISPLATIN 
5FU 
APER 4 Months 
10 RUKMANI 65/F Bleeding PR Lower 
Rectum 
T3N1M0 - 50.4 28 OXALIPLATIN 
CAPACITABINE 
APER 4 Months 
11 SESHAKUMAR 37/M Incomplete 
evacuation 
Lower 
Rectum 
T3N1M0 - 50.4 28 OXALIPLATIN  
CAPACITABINE 
APER  4 Months 
12 DURAISAMY 55/M Difficulty in 
passing 
motion 
Lower 
Rectum 
T3 N0 M0 HT 50.4 28 CAPACITABINE  
OXALIPLATIN 
APER   4 Months 
13 LALITHA 60/F  Bleeding PR Lower 
Rectum 
T3N1 MX HT 50.4 28 CISPLATIN 
5FU 
APER 4 Months  
14 ARUMUGAM 66/M Bleeding PR Lower 
Rectum 
T3NXM0 HT 50.4 28 CISPLATIN 
5FU 
  APER  4 Months 
15 MANI 57/M Bleeding PR Middle and 
Lower 
Rectum 
T3N1M0 - 50.4 28 CISPLATIN 
5FU 
Anterior resection 4 Months 
  
Number 
SURGERY 
DURATION 
(minutes) 
BLEEDING 
(ml) 
ILEOSTOMY 
WOUND 
INFECTION 
LEAK  
RATE 
SPHINCTER 
PRESERVATION 
HISTOLOGY 
(diifferentiation ) 
Referral pattern Previous surgery diet 
1 APR    150       400 - 
 
-   Well Self nil Mixed 
2 AR    170      500 + + _ + Well Self Nil Mixed 
3 APR    200      600 - -   Well Self Nil Mixed 
4 APR    120      300  -   moderate Self Nil Mixed 
5 AR    170      300 + -  + Well Doctor Haemorrhoidectomy Mixed 
6 AR    140      250 + + + + Well Self Nil Mixed 
7 AR     140      280 + -  + Moderate Self Nil Mixed 
8 APR    120     320  -   Well Doctor Haemorrhoidectomy Mixed 
9 APR    120     330  -   moderate Self Nil Mixed 
10 APR    110     200  -   Well Self  
nil 
Mixed 
11 APR    130     250  -   Poor Doctor Haemorrhoidectomy Mixed 
12 APR    120     270  -   Well Self nil Mixed 
13 APR   110      250     moderate Self nil Mixed 
14 APR   130      200  +   Well Doctor Haemorrhoidectomy Mixed 
15 AR   170      280 + + + + well Self Nil Mixed 
 
ABDOMINO PERINEAL RESECTION OF RECTUM 
 
ANTERIOR RESECTION OF RECTUM 
 
TOTAL MESORECTAL EXCISION  
 
PRE TREATMENT  
 
POST TREATMENT  
 
 
 
X-RAY CHEST 
 
 
RT SIMULATION 
 
 
  
 
 
 
